These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2674609)

  • 21. Ascertainment of the effect of differential growth rates of mutants on observed mutant frequencies in X-irradiated mammalian cells. An indication for the occurrence of X-ray-induced untargeted mutagenesis.
    Knaap AG; Simons JW
    Mutat Res; 1983 Aug; 110(2):413-22. PubMed ID: 6877264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of the genotoxicity of vincristine and colchicine using mouse lymphoma tk mutation assay].
    Wang YJ; Zhang LS
    Wei Sheng Yan Jiu; 2006 Mar; 35(2):179-81. PubMed ID: 16758965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [TK locus mutation assay: comparison of L5178Y and TK6 cell lines].
    Shuai PQ; Zhang LS; Wang YJ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Sep; 35(5):650-3. PubMed ID: 15460410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thymidine kinase gene mutation assay--comparison of microwell method and soft agar method].
    Shuai P; Zhang L; Wang Y
    Wei Sheng Yan Jiu; 2004 May; 33(3):350-2. PubMed ID: 15211812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The mutagenic and carcinogenic activity of chemical compounds].
    Rakitskiĭ VN; Turusov VS
    Vestn Ross Akad Med Nauk; 2005; (3):7-9. PubMed ID: 15852703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mouse lymphoma assay.
    Lloyd M; Kidd D
    Methods Mol Biol; 2012; 817():35-54. PubMed ID: 22147567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of ouabain-resistant mutants of the mouse lymphoma cell line L5178Y.
    Muriel WJ; Cole J; Lehmann AR
    Mutagenesis; 1987 Sep; 2(5):383-9. PubMed ID: 2830454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of chromosome aberration frequency and small-colony TK-deficient mutant frequency in L5178Y/TK(+/-)-3.7.2C mouse lymphoma cells.
    Moore MM; Doerr CL
    Mutagenesis; 1990 Nov; 5(6):609-14. PubMed ID: 2263219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene-mutation induction by arsenic compounds in the mouse lymphoma assay.
    Soriano C; Creus A; Marcos R
    Mutat Res; 2007 Dec; 634(1-2):40-50. PubMed ID: 17851118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The L5178Y S/S murine leukemic lymphoblast: a radiosensitive, malignant cell of stable karyotype.
    Rutledge MH; Lett JT
    Radiat Res; 1980 Feb; 81(2):282-91. PubMed ID: 7360885
    [No Abstract]   [Full Text] [Related]  

  • 31. Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2'-deoxycoformycin and deoxyadenosine in vitro.
    Begleiter A; Pugh L; Israels LG; Johnston JB
    Cancer Res; 1988 Jul; 48(14):3981-6. PubMed ID: 3260129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-ray and UV mutagenesis in two L5178Y cell strains differing in tumorigenicity, radiosensitivity, and DNA repair.
    Beer JZ; Jacobson ED; Evans HH; Szumiel I
    Br J Cancer Suppl; 1984; 6():107-11. PubMed ID: 6582899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro mammalian cell genotoxicity assays: their use and interpretation.
    McGregor D
    Prog Clin Biol Res; 1990; 340B():159-69. PubMed ID: 2203003
    [No Abstract]   [Full Text] [Related]  

  • 34. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The OSIRIS Weight of Evidence approach: ITS mutagenicity and ITS carcinogenicity.
    Buist H; Aldenberg T; Batke M; Escher S; Klein Entink R; Kühne R; Marquart H; Pauné E; Rorije E; Schüürmann G; Kroese D
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):170-81. PubMed ID: 23357514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro carcinogenicity testing: present and future perspectives in pharmaceutical development.
    Kowalski LA
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):29-35. PubMed ID: 11727320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmaceutical companies often provide insufficient information about genotoxicity and carcinogenicity assays.
    Brambilla G; Martelli A
    Lancet Oncol; 2003 Aug; 4(8):460-1. PubMed ID: 12901959
    [No Abstract]   [Full Text] [Related]  

  • 38. Bayes' Theorem for predicting human carcinogenicity.
    Ennever FK; Rosenkranz HS
    Mutagenesis; 1989 May; 4(3):241-3. PubMed ID: 2659943
    [No Abstract]   [Full Text] [Related]  

  • 39. Precedents or possibilities: which should guide the harmonization of mutagenicity test protocols and carcinogen prediction strategies?
    Ashby J
    Mutat Res; 1993 Feb; 298(4):291-5. PubMed ID: 7678166
    [No Abstract]   [Full Text] [Related]  

  • 40. Propositions in genetic toxicology and their erasure.
    Ashby J
    Mutat Res; 1994 Jul; 308(1):113-4. PubMed ID: 7516481
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.